Positive Phase II results for esketamine dry powder inhalation (Falkieri) in the acute phase of treatment-resistant bipolar depression

The study (n=88) met its primary endpoint of a reduction in Montgomery-Asberg Depression Rating Scale total score versus placebo at week 2 (largest difference for 48mg dose: placebo-subtracted difference of -8.2 (95% CI -12.6 to -3.7; p<0.001).

Biospace Inc.